A Prospective Clinical Cohort and Biorepository of Multiple System Atrophy (MSA). (P6.077)

Objective: To establish a clinical and biospecimen database of probable or possible MSA 1 . Background: MSA is a rare adult-onset neurodegenerative alpha-synucleinopathy, which progresses rapidly and presents with a varying combination of parkinsonism, cerebellar ataxia, autonomic failure, and pyramidal signs. Though prospective biorepositories exist for Parkinson’s disease 2, 3 , there are few such resources for MSA in the US 4 . Design/Methods: Subjects were recruited after signing informed consent. Study approval was obtained from the Columbia University IRB. Clinical data included neurological history, Montreal Cognitive Assessment (MOCA), and part II (Motor Examination Scale) of the Unified Multiple System Atrophy Rating Scale (UMSARS) 5 . Blood samples were collected for plasma, peripheral blood mononuclear cells (PBMC) and DNA, and stored for future research use per standard protocols. Results: Over a 2-year period, we enrolled 34 MSA patients (23 MSA-C, 8 MSA-P and 2 mixed phenotype). 56% are male, average age of onset is 59.8 (range 45–75), average disease duration is 4.4 years (range 1–9) and average MoCA score is 25.9 (range 19–30). There is no correlation between MoCA score and age (Pearson’s r= −0.29, p=0.14), disease duration (Pearson’s r = −0.24, p=0.22), or age at onset (Pearson’s r=−0.28, p=0.16). Average UMSARS part II score is 22.8 (range 8–46). There is a correlation between UMSARS part II score and age (Pearson’s r=0.37, p=0.05) and disease duration (Pearson’s r=0.74, p Conclusions: We present early findings of our MSA cohort at Columbia University. Disclosure: Dr. Kim has nothing to disclose. Dr. Gupta has nothing to disclose. Dr. Liong has nothing to disclose. Dr. Ma has nothing to disclose. Dr. Kang has nothing to disclose. Dr. Kuo has nothing to disclose. Dr. Alcalay has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Denali, Prophase, Genzyme Sanofi. Dr. Sklerov has nothing to disclose.